OBJECTIVE: To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. STUDY DESIGN: A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 months) admitted to the hospital for treatment of viral bronchiolitis were recruited from 3 regional pediatric centers over 3 bronchiolitis seasons (December 2003 to May 2006). Patients were randomized to receive, in a double-blind fashion, repeated doses of nebulized 3% HS (treatment group) or 0.9% normal saline (NS; control group), in addition to routine therapy ordered by the attending physician. The principal outcome measure was hospital length of stay (LOS). RESULTS: On an intention-to-treat basis, the infants in the HS group had a clinically relevant 26% reduction in LOS to 2.6 +/- 1.9 days, compared with 3.5 +/- 2.9 days in the NS group (P = .05). The treatment was well tolerated, with no adverse effects attributable to the use of HS. CONCLUSIONS: The use of nebulized 3% HS is a safe, inexpensive, and effective treatment for infants hospitalized with moderately severe viral bronchiolitis.
RCT Entities:
OBJECTIVE: To investigate the use of nebulized 3% hypertonic saline (HS) for treating viral bronchiolitis in moderately ill hospitalized infants by a prospective, randomized, double-blinded, controlled, multicenter trial. STUDY DESIGN: A total of 96 infants (mean age, 4.7 months; range, 0.3 to 18 months) admitted to the hospital for treatment of viral bronchiolitis were recruited from 3 regional pediatric centers over 3 bronchiolitis seasons (December 2003 to May 2006). Patients were randomized to receive, in a double-blind fashion, repeated doses of nebulized 3% HS (treatment group) or 0.9% normal saline (NS; control group), in addition to routine therapy ordered by the attending physician. The principal outcome measure was hospital length of stay (LOS). RESULTS: On an intention-to-treat basis, the infants in the HS group had a clinically relevant 26% reduction in LOS to 2.6 +/- 1.9 days, compared with 3.5 +/- 2.9 days in the NS group (P = .05). The treatment was well tolerated, with no adverse effects attributable to the use of HS. CONCLUSIONS: The use of nebulized 3% HS is a safe, inexpensive, and effective treatment for infants hospitalized with moderately severe viral bronchiolitis.
Authors: Jonathan M Mansbach; Pedro A Piedra; Stephen J Teach; Ashley F Sullivan; Tate Forgey; Sunday Clark; Janice A Espinola; Carlos A Camargo Journal: Arch Pediatr Adolesc Med Date: 2012-08
Authors: Max Wohlauer; Ernest E Moore; Christopher C Silliman; Miguel Fragoso; Fabia Gamboni; Jeffrey Harr; Frank Accurso; Frank Wright; James Haenel; David Fullerton; Anirban Banerjee Journal: Crit Care Med Date: 2012-09 Impact factor: 7.598
Authors: Margaret Rosenfeld; Stephanie Davis; Lyndia Brumback; Stephen Daniel; Ron Rowbotham; Robin Johnson; Sharon McNamara; Renee Jensen; Carol Barlow; Felix Ratjen Journal: Pediatr Pulmonol Date: 2011-03-01
Authors: Philip Jacobs; Douglas Lier; Katherine Gooch; Katharina Buesch; Michelle Lorimer; Ian Mitchell Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471